Metraipolis › archive › dc_dba6da207b53

Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors? — Europe PMC PMID:42142195

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42142195
DOI
10.1007/s11060-[numero omesso]-4
License (as archived)
solo-consultazione
Archived
2026-11-01T17:12:18.043Z
SHA-256 of the archived text
41b22ff7a783c4b53bed4f4b6a26ccac8fb108bc01724fcd58bc8e6fb43dce91
Stable URL of this page
https://metraipolis.com/documento/dc_dba6da207b53

How to cite

Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors? — Europe PMC PMID:42142195 — Europe PMC (en), https://europepmc.org/article/MED/42142195 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dba6da207b53 (Metraipolis archive dc_dba6da207b53, sha256 41b22ff7a783c4b53bed4f4b6a26ccac8fb108bc01724fcd58bc8e6fb43dce91)
BibTeX
@misc{dcdba6da207b53,
  title = {Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors? — Europe PMC PMID:42142195},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42142195},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dba6da207b53; sha256 41b22ff7a783c4b53bed4f4b6a26ccac8fb108bc01724fcd58bc8e6fb43dce91},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42142195. Agents can read the archived copy with the MCP tool read_document.